META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis

Arthritis and Rheumatism

Volumn 62, Issue 6, 2010, Pages 1683-1692

  Konda, Veera Reddy ^a   Desai, Anuradha ^a   Darland, Gary ^a   Bland, Jeffrey S ^a   Tripp, Matthew L ^a  

^a MetaProteomics LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIINFLAMMATORY AGENT; BETA CATENIN; BIOLOGICAL MARKER; BRUTON TYROSINE KINASE; CARRAGEENAN; CELECOXIB; COLLAGEN; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; MET 060; META 060; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROSTAGLANDIN E2; PROTEIN KINASE SYK; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE DEFECT; CARTILAGE DEGENERATION; CELL TRANSFORMATION; CHONDROGENESIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PAW EDEMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; BONE AND BONES; CARTILAGE; CELL DIFFERENTIATION; CYCLOPENTANES; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-6; MATRIX METALLOPROTEINASES; MICE; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND;

EID: 77952917692     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27441     Document Type: Article

References (43)

1. Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, on behalf of the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-2376
2. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47:72-75
3. Bajpai M, Chopra P, Dastidar SG, Ray A. Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin Investig Drugs 2008;17:641-659 (Pubitemid 351843609)
4. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004; 10:617-624 (Pubitemid 38796853)
5. Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 2000;175:120-127
6. Pan Z. Bruton's tyrosine kinase as a drug discovery target. Drug News Perspect 2008;21:357-362
7. Wossning T, Herzog S, Kohler F, Meixlsperger S, Kulathu Y, Mittler G, et al. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med 2006;203:2829-2840 (Pubitemid 46026161)
8. Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am J Respir Crit Care Med 2006;173:56-63. (Pubitemid 43069788)
9. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006;317:571-578
10. Mocsai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, Spusta SC, et al. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A 2004;101:6158-6163 (Pubitemid 38520544)
11. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007;124:244-257 (Pubitemid 47247604)
12. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 2005;11:936-943
13. Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 2005;6: 777-784 (Pubitemid 43090463)
14. Cuzzocrea S, Mazzon E, Di Paola R, Muia C, Crisafulli C, Dugo L, et al. Glycogen synthase kinase-3β inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin Immunol 2006;120:57-67. (Pubitemid 43903390)
15. Tripp M, Darland G, Lerman R, Lukaczer D, Bland J, Babish J. Hop and modified hop extracts have potent in vitro antiinflammatory properties. Acta Hortic 2005;668:217-228
16. Desai A, Konda VR, Darland G, Austin M, Prabhu KS, Bland JS, et al. META060 inhibits multiple kinases in the NF-κB pathway and suppresses LPS-mediated inflammation in vitro and ex vivo. Inflamm Res 2009;58:229-234
17. Takahashi N, Udagawa N, Kobayashi Y, Suda T. Generation of osteoclasts in vitro, and assay of osteoclast activity. Methods Mol Med 2007;135:285-301.
18. Voll RE, Kalden JR. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis? Ann N Y Acad Sci 2005;1051:799-810.
19. Sanghi S, MacLaughlin EJ, Jewell CW, Chaffer S, Naus PJ, Watson LE, et al. Cyclooxygenase-2 inhibitors: a painful lesson. Cardiovasc Hematol Disord Drug Targets 2006;6:85-100.
20. Bingham R. The face-off. Health Aff (Millwood) 2008;27:210-215
21. Duan Y, Liao AP, Kuppireddi S, Ye Z, Ciancio MJ, Sun J. β-Catenin activity negatively regulates bacteria-induced inflammation. Lab Invest 2007;87:613-624 (Pubitemid 46788789)
22. Ikeda F, Nishimura R, Matsubara T, Hata K, Reddy SV, Yoneda T. Activation of NFAT signal in vivo leads to osteopenia associated with increased osteoclastogenesis and bone-resorbing activity. J Immunol 2006;177:2384-2390 (Pubitemid 44200999)
23. Shiozawa S, Tsumiyama K. Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. Cell Cycle 2009;8:1539-1543
24. Dugo L, Abdelrahman M, Murch O, Mazzon E, Cuzzocrea S, Thiemermann C. Glycogen synthase kinase-3β inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 2006;25:485-491 (Pubitemid 43755919)
25. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, et al. GSK-3β inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005;33: 1903-1912 (Pubitemid 41306508)
26. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076-2081
27. Doyle SL, Jefferies CA, O'Neill LA. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFκB activation by lipopolysaccharide. J Biol Chem 2005;280:23496-23501
28. Frey RS, Gao X, Javaid K, Siddiqui SS, Rahman A, Malik AB. Phosphatidylinositol 3-kinase γ signaling through protein kinase Cζ induces NADPH oxidase-mediated oxidant generation and NF-κB activation in endothelial cells. J Biol Chem 2006;281: 16128-16138 (Pubitemid 43848508)
29. Takada Y, Aggarwal BB. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-κB activation, and apoptosis. J Immunol 2004;173:1066-1077 (Pubitemid 38924281)
30. Wei S, Siegal GP. Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets. Pathol Res Pract 2008;204:695-706.
31. Kulkarni NH, Onyia JE, Zeng Q, Tian X, Liu M, Halladay DL, et al. Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 2006;21:910-920
32. Lee SH, Kim T, Jeong D, Kim N, Choi Y. The Tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation. J Biol Chem 2008;283:11526-11534
33. Tsuboi H, Matsui Y, Hayashida K, Yamane S, Maeda-Tanimura M, Nampei A, et al. Tartrate resistant acid phosphatase (TRAP) positive cells in rheumatoid synovium may induce the destruction of articular cartilage. Ann Rheum Dis 2003;62:196-203.
34. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 2008;9:47-54. (Pubitemid 351266969)
35. Stanczyk J, Kowalski ML, Grzegorczyk J, Szkudlinska B, Jarzebska M, Marciniak M, et al. RANTES and chemotactic activity in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Mediators Inflamm 2005;2005:343-348 (Pubitemid 41803403)
36. Yao TC, Kuo ML, See LC, Ou LS, Lee WI, Chan CK, et al. RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. Arthritis Rheum 2006;54: 2585-2593
37. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993;90:11924-11928
38. Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999;42: 1635-1643
39. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-468 (Pubitemid 28093348)
40. Dey A, Tergaonkar V, Lane DP. Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-κB pathways. Nat Rev Drug Discov 2008;7:1031-1040
41. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008;4:691-699
42. Petrelli A, Giordano S. From single-to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-432 (Pubitemid 351472408)
43. Arbiser JL. Why targeted therapy hasn't worked in advanced cancer. J Clin Invest 2007;117:2762-2765